Statement: the primary trial did not use overall response rate, tumour response rate or preference score as its outcome measurement.
Primary_evidence: Outcome Measurement:    Progression-Free Survival (PFS) Rate   PFS was based on Kaplan-Meier estimates. PFS was defined as time in weeks from start of study treatment to first documentation of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 7. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD]), or from death case report forms (CRFs). Percentage of participants who had not experienced progression or death by Week 16 is reported.   Time frame: Baseline up to Week 16 Results 1:    Arm/Group Title: Bosutinib   Arm/Group Description: Four bosutinib 100 milligram (mg) capsules, equivalent to 400 mg bosutinib orally once daily for 48 weeks, or until disease progression, unacceptable toxicity or withdrawal of consent occurred.   Overall Number of Participants Analyzed: 73   Measure Type: Number   Unit of Measure: percentage of participants  39.6        (28.1 to 50.8)